Imiquimod is indicated for the treatment of specific forms of actinic keratosis, basal cell carcinoma, and genital warts. Imiquimod is a toll-like receptor (TLR) agonist that stimulates the innate and adaptive immune systems. Imiquimod induces the production of interferon alpha (IFN-α), interleukin- 12 (IL-12), and tumor necrosis factor-alpha (TNF-α), with a resulting cytokine cascade that may induce and/or support a cytotoxic T-lymphocyte (Th1) immune response. Although the exact mechanism of action is not fully elucidated, imiquimod may indirectly stimulate effector cells such as monocytes/macrophages, and dendritic cells to produce cytokines and chemokines.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), and to obtain the following information:
To order an OEL monograph for this compound, just click the ADD TO CART button.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’s OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.